论文部分内容阅读
目的 观察龙津降纤酶对急性缺血性卒中的治疗效果。 方法 选择诊断明确的急性缺血性卒中病人 80例 ,随机分为 2组 :对照组 4 0例 ,5%葡萄糖液 50 0 ml加血塞通注射液 0 .4 g静脉滴注 ,连用 1 4天 ;降纤酶组 4 0例 ,入院后第 1～ 3天分别给降纤酶 1 0 u加入生理盐水 1 0 0 ml,静脉滴注 1 h以上 ,按临床神经功能缺失程度评分标准于治疗前及治疗后 1 4天进行疗效评定。 结果 降纤酶组总有效率达 92 .5%,显效率为 72 .5%,明显优于对照组 ( 67.5%,3 7.5%) ,并可显著降低血纤维蛋白原 ,而对血小板计数、出、凝血时间、凝血酶原时间无明显影响 ,治疗中未见明显不良反应。 结论 龙津降纤酶对急性缺血性卒中治疗有效、安全。
Objective To observe the therapeutic effect of Longjin defibrase on acute ischemic stroke. Methods Eighty patients with definite diagnosis of acute ischemic stroke were randomly divided into 2 groups: control group 40 cases, 50% 5% glucose solution and Xuesaitong injection 0. 4 g intravenous infusion, once every 14 days Day; defibrase group 40 cases, 1 to 3 days after admission were given defibrase 10 u normal saline 100 ml, intravenous infusion of more than 1 h, according to clinical neurological deficit score standards in the treatment Efficacy assessment was performed before and after treatment for 14 days. Results The total effective rate of defibrase group was 92.5%, the effective rate was 72.5%, which was significantly better than that of the control group (67.5%, 7.5%), and significantly lower fibrinogen, while the platelet count, Out, clotting time, prothrombin time no significant effect, no obvious adverse reactions in the treatment. Conclusion Longjin defibrase is effective and safe in the treatment of acute ischemic stroke.